Walter M. Stadler to Cyclin-Dependent Kinase Inhibitor p16
This is a "connection" page, showing publications Walter M. Stadler has written about Cyclin-Dependent Kinase Inhibitor p16.
Connection Strength
0.212
-
Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res. 2001 Jun; 7(6):1676-82.
Score: 0.046
-
A G2/M growth arrest response to low-dose intermittent H2O2 in normal uroepithelial cells. Int J Oncol. 2000 Sep; 17(3):425-32.
Score: 0.043
-
Overcoming cellular senescence in human cancer pathogenesis. Genes Dev. 1998 Jan 15; 12(2):163-74.
Score: 0.036
-
Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res. 1996 Jul 01; 56(13):2886-90.
Score: 0.032
-
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res. 1996; 24(4):239-44.
Score: 0.031
-
Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clin Genitourin Cancer. 2006 Sep; 5(2):150-4.
Score: 0.016
-
Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res. 1995 Feb 01; 55(3):493-7.
Score: 0.007